Last reviewed · How we verify
Standard BP control
Standard BP control, marketed by the Second Affiliated Hospital of Nanchang University, holds a position in the hypertension management market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Standard BP control |
|---|---|
| Also known as | Enalapril-folic acid,amlodipine,hydrochlorothiazide, Standard target for reducing SBP, Control of home SBP to a target of 135mmHg |
| Sponsor | Second Affiliated Hospital of Nanchang University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML (PHASE2)
- CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension (NA)
- Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (PHASE2)
- Nurse-Led mHealth for Vulnerable-Phase Heart Failure (NA)
- Coaching and Navigation by Community Health Workers (CHWs) Through Telehealth for High-risk Hypertension (NA)
- Telemedicine in High-Risk Cardiovascular Patients Post-ACS (NA)
- Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |